Savolitinib clinical trials
Also written HMPL-504, Volitinib and AZD6094.
How each study uses savolitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the savolitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
39 studies that test it; most in 2019 (6)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 6 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 25 · Other 14
AstraZeneca (15) · Hutchison Medipharma Limited (9) · National Cancer Institute (NCI) (3) · Samsung Medical Center (3) · Hutchmed (1) · Canadian Cancer Trials Group (1) · Assistance Publique Hopitaux De Marseille (1) · Guangdong Association of Clinical Trials (1)
Often tested with
Tested in the same studies.
Durvalumab (2) · Tremelimumab (2) · Crizotinib (2) · Docetaxel (2) · Osimertinib (1) · Adavosertib (1) · Darolutamide (1) · Ocifisertib fumarate (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test savolitinib.
- Dec 2026Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)Phase 2 · Jeeyun Lee
- Jan 2027Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCPhase 2 · AstraZeneca
- Aug 2027Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET OverexpressionPhase 1/2 · The First Affiliated Hospital of Guangzhou Medical University
- Nov 2027Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.Phase 2 · Sun Yat-sen University
Studies
Open first, then newest update. How each study uses savolitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 39
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as SavolitinibHow we know
- Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)RecruitingPhase 2Jeeyun LeeNCT05620628Written as SavolitinibHow we know
- Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET OverexpressionRecruitingPhase 1/2The First Affiliated Hospital of Guangzhou Medical UniversityNCT05777278Written as SavolitinibHow we know
- Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingPhase 3AstraZenecaNCT05043090Written as savolitinibHow we know
- Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLCActive, not recruitingPhase 3HutchmedNCT05009836Written as SavolitinibHow we know
- Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCActive, not recruitingPhase 2AstraZenecaNCT05374603Written as SavolitinibHow we know
- Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentActive, not recruitingPhase 3AstraZenecaNCT05261399Written as SavolitinibHow we know
- Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03598244Written as SavolitinibHow we know
- A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCActive, not recruitingPhase 2AstraZenecaNCT04606771Written as Osimertinib + SavolitinibHow we know
- Savolitinib vs. Sunitinib in MET-driven PRCC.Active, not recruitingPhase 3AstraZenecaNCT03091192Written as SavolitinibHow we know
- Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationCompletedPhase 3Hutchison Medipharma LimitedNCT05015608Written as Savolitinib + OsimertinibHow we know
- Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma PatientsCompletedPhase 2Hutchison Medipharma LimitedNCT04923932Written as SavolitinibHow we know
- Prostate Cancer Biomarker Enrichment and Treatment SelectionActive, not recruitingPhase 2Canadian Cancer Trials GroupNCT03385655Written as SavolitinibHow we know
- A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy VolunteersCompletedPhase 1AstraZenecaNCT06348355Written as [11C]savolitinibHow we know
- Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PatientsCompletedPhase 3Hutchison Medipharma LimitedNCT04923945Written as SavolitinibHow we know
- Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedCompletedPhase 2National Cancer Institute (NCI)NCT02761057Written as SavolitinibHow we know
- MEDI4736 Combinations in Metastatic Renal Cell CarcinomaCompletedPhase 2Queen Mary University of LondonNCT02819596Written as SavolitinibHow we know
- Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceActive, not recruitingPhase 2Assistance Publique Hopitaux De MarseilleNCT03833440Written as SavolitinibHow we know
- Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLCActive, not recruitingPhase 2Guangdong Association of Clinical TrialsNCT05163249Written as SavolitinibHow we know
- Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal CancerTerminatedPhase 2National Cancer Institute (NCI)NCT03592641Written as SavolitinibHow we know
See all 39 studies that test savolitinib →
Given beside what is tested · 4 — savolitinib is usual care or a partner of the new treatment
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491Written as SavolitinibHow we know
- Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibActive, not recruitingPhase 2AstraZenecaNCT03778229Written as SavolitinibHow we know
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingPhase 2AstraZenecaNCT03944772Written as SavolitinibHow we know
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedPhase 2UNICANCERNCT02117167Written as savolitinibHow we know
Codes
What other systems call savolitinib · ClinicalTrials.gg INT000122
- MeSH (NLM) C0005932591-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazineConfirmed NLM, Wikidata
- UNII (FDA) 2A2DA6857RSAVOLITINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27254463savolitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C104732SavolitinibOne source FDA
- DrugBank DB12048One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000593259 | 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine | Confirmed NLM, Wikidata |
| UNII (FDA) | 2A2DA6857R | SAVOLITINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27254463 | savolitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C104732 | Savolitinib | One source FDA |
| DrugBank | DB12048 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.